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This study explored a novel system combining plant-based production and the elastin-like peptide (ELP) fusion strategy to produce
vaccinal antigens against tuberculosis. Transgenic tobacco plants expressing the mycobacterial antigens Ag85B and ESAT-6 fused
to ELP (TBAg-ELP) were generated. Purified TBAg-ELP was obtained by the highly eﬃcient, cost-eﬀective, inverse transition
cycling (ICT) method and tested in mice. Furthermore, safety and immunogenicity of the crude tobacco leaf extracts were assessed
in piglets. Antibodies recognizing mycobacterial antigens were produced in mice and piglets. A T-cell immune response able
to recognize the native mycobacterial antigens was detected in mice. These findings showed that the native Ag85B and ESAT-
6 mycobacterial B- and T-cell epitopes were conserved in the plant-expressed TBAg-ELP. This study presents the first results
of an eﬃcient plant-expression system, relying on the elastin-like peptide fusion strategy, to produce a safe and immunogenic
mycobacterial Ag85B-ESAT-6 fusion protein as a potential vaccine candidate against tuberculosis.
1. Introduction
Tuberculosis (TB) remains one of the major infectious
diseases, which continues to pose a major global health
problem. Mycobacterium tuberculosis is the main TB-causing
micro-organism in human. However, the zoonotic disease
bovine TB, caused by the closely related M. bovis, poses a
significant threat to human health and can be responsible for
up to 10% of human TB cases [1–4]. Therefore, both human
and bovine TB should be targeted for an eﬃcient control
strategy. Here, vaccination remains the most promising
approach and also the most common. Bovine TB might also
be an eﬃcient model for human TB, allowing the testing of
innovative vaccines [5, 6].
The only available vaccine against TB is still the M. bovis
Bacillus Calmette-Guerin (BCG). It has been distributed
since the 1920s and more than three billion people have
received this vaccine. BCG vaccination, however, remains
a matter of debate due to safety aspects, loss of sensitivity
to tuberculin as a diagnostic reagent, and varying eﬃcacy
(from 0 to 85%) in diﬀerent BCG vaccine trials [7, 8].
Better TB vaccines are urgently needed. Subunit vaccines are
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a promising strategy since, in contrast to BCG, they are not
compromised by exposure to environmental mycobacteria
[8, 9]. They can also be retained as a booster to BCG priming,
thus prolonging immunity to also cover the adult population
[9].
Several TB subunit vaccines have been developed, mainly
based on M. tuberculosis-secreted components such as the
early secretory antigenic target, ESAT-6, and the antigen 85B
(Ag85B). Both antigens have an impressive track record of
studies, also in humans, confirming their antigenicity and
vaccine potential [9–11]. ESAT-6 and Ag85B, both common
to M. tuberculosis and M. bovis, might lead to eﬀective
vaccines against human and bovine TB.
However, even though eﬃcient vaccinal antigens have
been identified, the cost constraints related to vaccine
production, distribution, and delivery remain prohibitive to
widespread administration in developing countries where
vaccines are needed the most.
Plants might be attractive vehicles to overcome these
constraints. Since the first report about a plant-derived
vaccine [12, 13], a large number of species (i.e., tobacco,
corn, rice, lettuce, and alfalfa) have been used for vaccine
production and evaluated in diﬀerent hosts [14–16]. Plants
are easy and inexpensive to grow and are versatile systems
with minimum manufacture and processing requirements,
amenable to rapid and economical scale-up. They have
reduced risks of contamination with human or animal
pathogens. Regarding food plants, edible vaccines eliminate
the need for needles and skilled personnel for adminis-
tration and for refrigerated storage, which is particularly
attractive for developing countries [15, 17]. Vaccination
by oral delivery of plant-based vaccines to humans, or
by feeding large animals, has been proven eﬃcient [18–
20].
Various strategies have been described to express foreign
proteins in plants [16, 17]. Among them, fusion to elastin-
like peptides (ELP) has been proved promising. It has been
shown, in particular, to enhance the expression of spider
silk proteins [21, 22], human interleukin-10 and murine
interleukin-4 [21], single-chain variable fragment (scFv)
antibodies [23], and full-length antibodies [24, 25]. Synthetic
ELPs are designed around the characteristic VPGVP motif
found in native mammalian elastins [26], utilizing repeats of
the pentapeptide VPGXG, where X can be any amino acid
except proline [27]. A major advantage is the simple and
inexpensive purification procedure, called inverse transition
cycling (ITC), initially used for the purification of E. Coli-
expressed recombinant proteins [27]. This method has
been further improved for ELP-containing pharmaceutical
proteins expressed in plants [24, 27–29]. The use of ELPs, as
delivery vectors for chemotherapeutic drugs and therapeutic
peptides [30] or elastin-like polymers with emphasis on
medical uses [31], is well described and a main focus of
future research in human therapeutics [32]. In addition,
ELPs are biocompatible [33], making them suitable for in
vivo applications [34]. The ELP plant-based expression strat-
egy might thus be a valuable approach to develop vaccines
targeting diseases with enormous impact on developing
countries, such as TB.
For optimum plant expression, three main aspects have
to be considered: the G+C content, codon usage, and
presence of destabilizing AT-rich sequences. M. tuberculosis
and M. bovis are characterized by a high G+C% (64%
to 66%) whereas Nicotiana tabacum has a lower G+C%
(43.72%) [35]. This results in a clear diﬀerence of codon
usage and may generate unwanted recognition of AT-
rich-destabilizing sequences or other regulatory sequences,
known to be detrimental for expression. Such problems were
successfully overcome to develop insect-resistant BT cry-
transgenic crops by designing synthetic genes encoding the
same protein but with adapted plant codon usage and G+C
contents [36, 37].
In this study, we tested the eﬃcacy of the ELP fusion
strategy for expressing the Ag85B/ESAT-6 fusion protein
(TBAg) in transgenic tobacco plants. The plant-made TBAg-
ELP immunogenicity was assessed in mice, as a reference
laboratory model and piglets, as a preclinical model of
human vaccination. Swine, moreover, as natural hosts for
Mycobacterium species, might be representative of a human
TB model [38, 39]. In addition, as a first step towards cattle
application, in vitro experiments were also performed with
bovine immune cells. The aim of this study was to determine
the feasibility of using tobacco plant-based vaccines against
bovine and human TB based on the ELP strategy.
2. Materials andMethods
2.1. Production of Plant-Expressed TBAg-ELP Fusion Protein.
An Ag85B/ESAT-6 (TBAg) gene cassette was first synthe-
sized by the recursive asymmetric PCR method (Figure 1)
[40]. Briefly, the sequences, Ag85B (P31952) and ESAT-6
(AAL16896), were modified “in silico,” to optimize codon
usage for plants, eliminate the 6-base restriction sites, and
remove A+T-rich destabilizing sequences, while maintain-
ing the amino acid (aa) sequences (Windows Biological
Sequence Alignment tool, BioEdit). Sequences were then
divided into 3 blocks (267, 308, and 314 nt) for Ag85B
and one (314 nt) for ESAT-6. Each block was created in
vitro by asymmetric PCR using a total of five 65 to 70-
mer oligonucleotides, cloned into pGEM(T)-easy (Promega,
Charbonnie`res-les-Bains, France) and sequenced to ensure
the absence of mismatches. Blocks were flanked by “suicidal”
restriction sites to allow further assembly of the full-
length cassette. NsiI and ApaI restriction sites were created
upstream and downstream, respectively, to allow cloning into
pGEM(T)-easy and removal of the whole TBAg cassette.
The synthetic TBAg cassette was then inserted into
a plant expression system. The TBAg cassette was first
amplified by PCR using two specific primers, each con-
taining a BamHI site and, for the reverse primer, without
the stop codon. The cassette was cloned as a BamHI
fragment in the plasmid pRTRA-100xELP containing the
ubiquitous Cauliflower Mosaic Virus (CaMV) 35S promoter
[41, 42], the legumin B4 (LeB4) signal peptide [43], the
c-myc tag (EQKLISEEDLN; [44]), the sequence encoding
the 100xELP fusion protein, and the KDEL endoplasmic
reticulum (ER) retention signal to produce the construct
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Figure 1: Diagrammatic representation of the Ag85B/ESAT-6 fusion cassette. The strategy used was recursive asymmetric PCR. In silico
modified Ag85B and ESAT-6 gene sequences were divided into 3 blocks (267, 308, and 314 nt) for Ag85B and one (314 nt) for ESAT-6. Each
block was created by asymmetric PCR using five 65 to 70-mer primers then cloned into pGEM(T)-easy. Blocks were flanked by “suicidal”
restriction sites to allow further assembly of the full-length cassette. NsiI and ApaI restriction sites were created upstream and downstream,
respectively, to allow cloning into the pGEM(T)-easy and removal of the whole TBAg cassette.
pRTRA-TBAg-ELP. The 100xELP fusion protein, previously
described by Scheller and coworkers [22], contained 100
repeats of the pentapeptide VPGXG with X being glycine,
valine, or alanine. The expression cassette (Figure 2(a)) was
excised by HindIII and inserted into the binary vector
pCB301-Kan [45], which is based on the binary vector
pCB301 [46]. The resulting binary vector was introduced
into Agrobacterium tumefaciens C58C1 (pGV2260; [47]) and
functionally tested in transient expression assays by agroinfil-
tration [48, 49]. Stable transgenic tobacco plants (Nicotiana
tabacum cv. Samsun NN) were generated using the leaf
disk transformation method [50] and grown on Murashige-
Skoog medium [51] containing 50 mg/L kanamycin prior to
transfer to soil in the greenhouse. In parallel, a construct
lacking the 100xELP sequence was prepared and used for
Agrobacterium-mediated transformation of tobacco (D. Floss
and U. Conrad unpublished).
2.2. Purification and Characterization of TBAg-ELP
Fusion Protein from Tobacco Leaves
2.2.1. Preparation of Tobacco Leaf Extracts. Leaves from
TBAg-ELP transgenic tobacco plants and plants accumulat-
ing the 100xELP protein were prepared for in vivo immuno-
genicity assay and leaves from nongenetically modified plants
(wild-type, WT) were used for cytotoxicity evaluation.
The tobacco leaf extracts (TLEs) were prepared by
crushing frozen leaves (−80◦C or liquid nitrogen) and
homogenizing in 100 mM Tris. These TLEs were used for the
piglet cytotoxicity assay to assess the crudest preparation of
tobacco plant-based vaccine. Otherwise, TLEs were cleared
by filtration and centrifugation (20 minutes, 15,000 g, 4◦C).
For in vitro assays, an extraction buﬀer (50 mM Tris-HCl
pH8; 1 mM EDTA; 0.1% Triton X100; 1 mM DTT; 5%
glycerol) was used (Breitler, personal communication), then
TLEs were centrifuged and dialyzed overnight (Slide A Lyzer,
Perbio, France). The concentration of total soluble proteins
(TSPs) was determined by Bradford assay (Bio-Rad, Munich,
Germany) or NanoDrop (Thermo Fisher Scientific, Cergy,
France).
2.2.2. SDS-PAGE and Immunoblotting Analyses. Electro-
phoresis and Western blot were performed using TBAg-ELP
transgenic tobacco as previously described [22]. TBAg-ELP
protein was detected by the ECL Western blotting analysis
system using anti-c-myc (9E10) supernatant followed by
horseradish peroxidase- (HRP-) conjugated sheep antimouse
IgG (Amersham Biosciences, Piscataway, NJ, USA). The
TBAg-ELP in leaf extracts was quantified by comparison
between dilutions of the TLE-TBAg-ELP, from 2 μg to
0.25 μg of TSP, and the recombinant c-myc-tagged IL-6 as
standard.
2.2.3. Purification of the ELP Fusion Proteins by “Inverse
Transition Cycling” (ITC). The recombinant proteins TBAg-
ELP and 100xELP were purified from tobacco leaves by
inverse transition cycling (ITC), based on the salt- and
temperature-dependent phase transition of the elastin-like
polypeptides [27] as described [22, 24].
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Figure 2: Production of plant-expressed TBAg-ELP fusion protein. (a) Diagrammatic representation of the TBAg-ELP expression cassette.
Expression of the recombinant fusion protein was driven by the constitutive CaMV 35S promoter. Endoplasmic reticulum retrieval was
mediated by a C-terminal KDEL tag and the c-myc tag was included to facilitate detection. ELP fusion consisted of 100 repeats of the
pentapeptide VPGXG, where X was valine, glycine, or alanine (100xELP). (b) Accumulation increase of TBAg-ELP in transgenic tobacco
plants. Western blot analysis of leaf extracts of individual T0 plants expressing the transgene. Proteins were separated by reducing 10% SDS-
PAGE, blotted, and immunodetected using an anti-c-myc antibody. Numbers designate the independent T0 plants. The same amounts of
TSP were loaded on the gel (15 μg/lane). S: cmyc standard (15 ng/lane); Wt: wild-type N. tabacum.
2.3. Animals, Cell Preparation, and Analysis
2.3.1. Animals and Cell Preparation
(1) Mouse. BALB/c mice aged 6–8 weeks were used for
in vitro experiments and C57BL/6 mice aged 12 weeks
for in vivo immunization (Charles Rivers, Lyon, France).
Experiments were conducted in accordance with national
guidelines for animal care. BALB/c mice spleen cells were
obtained by spleen dissociation, nylon membrane pas-
sage, and red blood cell elimination. Spleen cells were
washed, counted, and resuspended in complete RPMI
(cRPMI) containing RPMI-1640-medium with 10% foetal
calf serum (FCS), 2 mM L-glutamine and 5 · 10−5 M 2-
mercaptoethanol (Eurobio, Les Ulis, France), 100 U/mL
penicillin G, and 100 μg/mL streptomycin (Sigma, St.
Quentin, France). Mouse bone marrow-derived dendritic
cells (mBM-DC) were generated as described in [52] by
depletion of lymphocytes, macrophages, and granulocytes
and 6 days’ culture in cRPMI containing the mouse recom-
binant granulocyte/macrophage colony-stimulating factor
(rmGM-CSF, 6 ng/mL) and interleukin-4 (rmIL-4, 3 ng/mL)
(R&D Systems, Lille, France).
(2) Cattle. Blood was taken into heparin-containing vacu-
tainer tubes (BD-Pharmingen, Le Pont de Claix, France)
from two naive cattle hosted at the CIRAD animal facility.
Peripheral blood mononuclear cells (PBMCs) were collected
by density gradient centrifugation as previously described
[53]. Bovine monocyte-derived dendritic cells (Bo-Mo-DC)
were prepared from CD14-expressing cells using 40 ng/mL of
both bovine recombinant IL-4 and GM-CSF as described in
[54].
(3) Piglets. Large white neonate piglets aged 10–31 days were
used to evaluate TLE toxicity and aged 33–61 days to assess
the immunogenicity of the plant-made TBAg-ELP. Piglets
were housed in the INRA experimental unit and received a
standard diet twice a day. During the experiment, animals
were cared for in accordance with the guidelines of the INRA
Institutional Animal Care and Use Committee.
2.3.2. Flow Cytometry Analysis. The mouse BM-derived
DC surface markers CD40, CD80, and CD86 and major
histocompatibility complex class II molecules (MHC II) were
stained using monoclonal antibodies (mAbs) conjugated
to fluorescein isothiocyanate (FITC) or phycoerythrin (PE)
(BD-Pharmingen, Le Pont de Claix, France). Bovine cell
surface markers were stained (10 minutes, RT) with mouse
antibovine mAbs to MHC II (ILRI, Nairobi, Kenya), CD40,
CD80, and CD86 (provided by J Hope, IAH, Compton, UK).
Cells were washed with PBS (without Ca, Mg) containing
1% BSA 0.1% sodium azide and revealed by FITC-antimouse
IgG (Tebu, Le Perray, France).
To determine cell proliferation, 2 × 107 cells were sus-
pended in Hanks-balanced salt solution (1 mL) and stained
with carboxyfluorescein diacetate succinimidyl ester (CFSE,
1 μM final, Invitrogen, Cergy-Pontoise, France). After 10
minutes at 37◦C, the reaction was stopped by an equal
volume of cold heat-inactivated FCS. Afterwards, cells were
washed in RPMI containing 10% FCS and processed for
stimulation assays.
To determine cytotoxicity, 2 μL of propidium iodide
(50 μg/mL, BD-Pharmingen, France) were added after the
last wash to each tube, kept at 4◦C, and protected from light
pending flow cytometry analysis.
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Flow cytometry analyses were performed on an FACscan
flow cytometer equipped with the CellQuest 3.01 software
(BD, San Jose, CA, USA) after acquisition of at least 5000
events within a typical forward and side scatter gate set to
exclude dead cells and debris. The results, expressed as means
and standard deviations, were the percentage of fluorescing
cells or, to assess proliferation, of cells that had undergone
cell divisions, that is, with decreased CFSE fluorescence
intensity.
2.4. In Vitro Assessment of an Immunomodulatory Impact of
Purified ELP Protein. In order to determine whether ELP by
itself might have an immunomodulatory role, the interaction
between ITC-purified ELP and mouse and bovine immune
cells was tested in vitro to evaluate lymphocyte proliferation
and dendritic cell maturation.
2.4.1. Eﬀect of ELP onMouse and Bovine Lymphocytes. Mouse
spleen cells and bovine PBMC were CFSE stained and
stimulated (3 × 105 cells/well) with purified ELP (5 μg/mL)
or with the mitogen ConA (positive control, 5 μg/mL, Sigma,
St. Quentin, France), or left untreated (negative control).
Cells were then processed by flow cytometry after 4 days of
incubation. Two duplicate experiments were performed in
each case.
2.4.2. Eﬀect of ELP on Mouse and Bovine Dendritic Cells.
In two duplicate experiments, mBM-DC and Bo-Mo-DC
(106 cells/well) were stimulated for 24 hours with purified
ELP (2.5 and 5 μg/mL) or left untreated (negative control).
The positive control was lipopolysaccharide (LPS, 2 μg/mL,
Sigma, St. Quentin, France) for mBM-DC and a mix of
LPS (2 μg/mL), IFNγ (100 U/mL, Serotec, Cergy, France)
and Zymosan (10 μg/mL, Sigma) for Bo-Mo-DC. Cells were
then immunostained and phenotyped by flow cytometry to
determine the expression of the cell surface markers (CMH
II, CD40, CD80, and CD86).
2.5. Cytotoxicity Evaluation of Tobacco Leaf Extracts (TLEs)
from Nontransgenic Plants. This experiment intended to
determine whether a crude tobacco leaf extract (TLE)
could be used for immunization or exhibit a potential for
cytotoxicity.
2.5.1. In Vitro Experiments on Mouse and Bovine Cells.
Mouse spleen cells and bovine PBMC (2 × 106 cells/mL)
were incubated at 37◦C for 4 days with TLE dilutions
(v/v) ranging from 0.01% to 6%. Cells were then processed
by flow cytometry for cytotoxicity analysis. Two duplicate
experiments were done for each animal.
2.5.2. In Vivo Experiments on Neonate Piglets. To evaluate
toxicity, two 10-day-old piglets received 3 intraperitoneal
(IP) injections of TLE at days 0, 7, and 14 and 2 control
piglets received PBS. The IP route was selected because it
is strongly linked to systemic circulation. Samples corre-
sponding to 45 mg of powdered tobacco leaves were used.
The TSP concentration ranged from 2 to 2.5 mg/mL. Piglets
were thus injected with crude TLE containing 3.6 mg of TSP.
Daily clinical observation and temperature recording were
performed from day 0 to 21.
2.6. Evaluation of the Immunogenicity of the Plant-Produced
TBAg-ELP Fusion Protein. Mouse experiments were per-
formed with ITC-purified TBAg-ELP, while piglet exper-
iments tested TLE-containing TBAg-ELP fusion protein
(TLE-TBAg-ELP).
2.6.1. Mouse Experiments. Five groups of 4 12-week-old
C57BL/6 mice were immunized as previously described [55].
Two groups were injected with 5 μg or 10 μg of TBAg-ELP,
two control groups with 5 μg or 10 μg of M. tuberculosis
culture filtrate proteins (CFP, Colorado State University,
Fort Collins, Colorado, USA), and the negative control
group with 0.9% NaCl. Antigens were delivered with DDA
(dimethyldioctadecylammonium bromide, 250 μg/dose) and
MPL (monophosphoryl lipid A, 25 μg/dose) (Sigma, St.
Quentin, France) by 3 subcutaneous injections (200 μL) on
day 0, 14, and 28. Blood was taken from the tail on day 0,
42, and 84, pooled for each group, and centrifuged to collect
sera.
A CFP-ELISA was mounted by coating plates with
CFP (1 μg/well), to test sera (1/50) in triplicate. Total
immunoglobulins (Ig) were detected with HRP-labeled rab-
bit antimouse polyclonal antibodies (Dako, Trappe, France).
Absorbance was measured at 450 nm after TMB (3,3′,5,5;-
Tetramethylbenzidine, Sigma, St. Quentin, France) revela-
tion and H2SO4 treatment.
A liposome system was tested in a second experi-
ment to deliver and enhance TBAg-ELP immunogenicity.
Cationic liposomes were made with DOTAP (N-[1-(2,3-
dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride,
Sigma), downsized by a procedure of freeze/thaw and
extrusion (LiposoFast extruder, Avestin, Ottawa, Canada)
[56], and mixed with TBAg-ELP. Four groups of 4 mice
were immunized, as described above, with 10 μg of TBAg-
ELP mixed with DDA/MPL or liposomes (10 μg). Controls
received 10 μg of CFP/DDA/MPL (positive) or 0.9% NaCl
(negative). Blood sampling and CFP ELISA were as described
above. A mouse skin test was also performed on day 56 to
evaluate the delayed-type hypersensitivity (DTH) reaction.
Mice received 10 μg of M. bovis-purified protein derivative
(PPD, BIOCOR 7090, Pfizer Animal Health) in 40 μL of 0.9%
NaCl by intradermal injection into the right-hind footpad
and, as a control, 0.9% NaCl in the left-hind footpad. The
diameter of the specific swelling was measured 24 hours later
and data were expressed as a mean (± SD) of the diﬀerence
between right and left footpads for each group.
2.6.2. Piglet Experiment. Eight piglets were divided into four
groups and each group was compared to the other groups
allowing a statistical analysis of the diﬀerence between
groups (n = 4, four groups). Group 1 was immunized with
E. coli recombinant ESAT-6 (CRBM, Montpellier, France),
group 2 with TLE-TBAg-ELP, group 3 with E. coli ESAT-6
and boosted twice with TLE-TBAg-ELP, and group 4 with
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PBS (negative control). Immunized groups received 360 μg of
antigen by the intradermal route on day 0, 7, and 14, a dose
estimated from a similar study in pigs [20]. For each group,
the first two immunizations contained an equal volume of
Freund complete adjuvant while the third immunization
contained Freund incomplete adjuvant (Sigma, St. Quentin,
France). Sera were harvested weekly until the piglets were
slaughtered on day 28.
To study porcine IgG responses to ESAT-6 and Ag85B,
plates (Maxisorp, Fischer Scientific Bioblock, Illkirsh,
France) were coated with E. coli recombinant ESAT-6 or
Ag85B (500 ng/mL, carbonate/bicarbonate buﬀer 0.1 M, pH
9.6, overnight, 4◦C) and blocked (PBS-0.5% milk, 1h30,
37◦C). To assess piglet IgG ability to recognize plant-
made TBAg epitopes, plates were coated with rabbit anti-
Ag85B antibodies (U. Conrad; 1 : 200, carbonate/bicarbonate
buﬀer 0.1 M, pH 9.6, overnight 4◦C) and blocked with
PBS-0.5% milk and TLE containing 2 μg/mL of TBAg-ELP
was added to each well (1h30, 37◦C). Sera were tested
at 10−2, 10−3, and 10−4 in PBS-Tween-1% BSA and IgG
were detected by HRP-conjugated goat antiswine IgG-Fc
antibodies (1 : 20000, Bethyl, Montgomery, USA). Optical
densities were read at 414 nm after incubation with 2,2′-
azino-di-[3-ethylbenzthiazoline-sulfonate].
For immunoblotting, E. coli recombinant ESAT-6
(100 ng) or Ag85B (100 ng) and TLE-TBAg-ELP (1 μg) were
run on a 15% SDS-PAGE, transferred to nitrocellulose
membrane, and incubated with piglet sera (1 : 1000 in
PBS-Tween-3% BSA, 1h30) collected on day 0 and 28.
Rabbit ESAT-6 (1 : 1000) and Ag85B (1 : 3000) antisera and a
cocktail of both for TBAg-ELP were used as positive controls.
HRP-conjugated goat antiswine antibodies (1 : 10000, Bethyl,
Montgomery, USA) and antirabbit antibodies (1 : 3000,
Dako, Trappe, France) were added (1h30) and revealed
by chemiluminescence using the Super Signal West Dura
(Pierce, Rockford, USA).
2.7. Statistical Analysis. Statistical analyses were based on
the Student’s t-Test (http://www.physics.csbsju.edu/stats/t-
test.html). P-values less than .05 were considered signif-
icant and less than .01 highly significant. For the piglet
experiment, data were analysed by variance analysis using
GraphPad Prism software version 3.00 (GraphPad Software
Inc., San Diego, CA, USA).
3. Results
3.1. Production of Plant-Expressed TBAg-ELP Fusion Protein.
The TBAg coding sequence (Figure 1) was inserted into a
plant expression cassette as depicted in Figure 2(a). The
functionality of the binary vector was verified by transient
agro-infiltration and the recombinant proteins were detected
by Western blot (data not shown).
Tobacco plants were genetically modified by Agrobac-
terium-mediated leaf disk transformation and generated
plants were screened for accumulation of the ELP fusion
protein. Constitutive expression of the TBAg-ELP fusion
protein in leaves of T0 plants was confirmed by Western
28
36
55
72
95
130
250
M
W
(k
D
a)
Standard
Leaf extract Leaf extract
8–1 12–1
20
n
g
40
n
g
80
n
g
0.
25
μ
g
0.
5
μ
g
1
μ
g
1.
5
μ
g
2
μ
g
TSP
0.
25
μ
g
0.
5
μ
g
1
μ
g
1.
5
μ
g
2
μ
g
TSP
Figure 3: Quantification of TBAg-ELP in crude extracts of
transgenic tobacco leaves. Dilutions of TLE-TBAg-ELP, from 2 μg to
0.25 μg of total soluble proteins (TSPs), were separated by reducing
10% SDS-PAGE, blotted, and immunodetected using an anti-c-myc
antibody. Recombinant c-myc-tagged IL-6 was used as standard.
The TBAg-ELP accumulation level was approximately 4% of TSP
of crude leaf extract. Analysed leaf materials came from oﬀspring
plant 8 and 12 of the T0 plant 26.
blot using an antibody against the c-myc tag (Figure 2(b)).
Fusion to 100xELP resulted in increased accumulation of
the TBAg compared to TBAg without ELP fusion (TBAg,
40.8 kDa, D. Floss & U. Conrad unpublished) (Figure 2(b))
as described previously for other recombinant proteins
[22–24]. The electrophoretic mobility of ELP fusion was
lower than expected (84 kDa versus approx. 100 kDa, Figures
2(a) and 2(b)) as observed for other ELP fusion proteins
expressed in bacteria and plants [24, 57, 58]. TBAg-ELP
was detected as a double band, which was probably a result
of diﬀerences in the N-glycan composition. Indeed, the
TBAg aa sequence contains 6 putative glycosylation sites.
Transgenic tobacco plants accumulating the recombinant
TBAg-ELP had a normal phenotype compared to wild-type
plants.
The concentration of TBAg in crude tobacco leaf extracts
was estimated by semiquantitative Western blot using dilu-
tions of a defined standard, c-myc-tagged IL-6 (Figure 3).
A TBAg-ELP accumulation level of approximately 4% of
total soluble leaf protein was suggested when comparing the
intensities of the bands. Since the ELP fusion protein was
quantified relative to the unfused standard, the total amount
of fusion protein is underestimated.
TBAg-ELP was purified from tobacco leaf material
by inverse transition cycling (ITC) [22, 24, 29] and the
resolubilized pellets were analysed by Western blot (data not
shown).
3.2. Assessment of an Immunomodulatory Role of the Elastin-
Like Protein (ELP). As a primary step, since the TBAg
was expressed as a fusion protein with the ELP motif, the
immunomodulatory eﬀect of ELP was assessed. For this
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Figure 4: Impact of purified ELP on mouse and bovine immune cells. (a) ELP eﬀect on cell proliferation in mouse spleen cells and bovine
PBMC. CFSE-stained mouse spleen cells and bovine PBMC were stimulated for 4 days with 5 μg/mL of purified ELP (ELP) or mitogen
ConA (ConA) or left untreated (Control). Cells were then collected and processed by flow cytometry for measurement of proliferating
cells. The histograms show the FL1 emission values (FL1-H) for one representative experiment for each animal cell type out of two duplicate
experiments. Results are expressed in percentage of cells that had undergone cell divisions, that is, with decreased CFSE fluorescence intensity.
The control histogram (unstimulated cells) was filled in grey; the doted black line corresponded to ELP and the grey solid line to ConA
stimulation. (b) ELP eﬀect on maturation marker expression in mouse bone marrow-derived dendritic cells (mBM-DCs). Mouse BM-DCs
(106 cells/well) were stimulated for 24 hours with purified ELP (2.5 and 5 μg/mL), LPS (control +) or left untreated (control −). Cells were
immunostained of the following cell surface markers: CMH II, CD40, CD80, CD86 and processed by flow cytometry as described in Material
and Methods. The histogram presents the mean (± SD) of the percentages of fluorescing cells for each cell surface marker for two experiments
done in duplicate.
purpose, ITC-purified ELP (containing the c-myc tag and
KDEL ER retention signal) was used.
The capacity of ELP to induce cell proliferation from
mouse spleen cells or bovine PBMC was assayed in two
duplicate experiments for each cell type. Figure 4(a) presents
the data for one representative experiment for each cell
type. The results showed that ConA stimulation (positive
control) triggered a strong lymphoproliferation (77% to 82%
for the mouse spleen cells and 85% to 87% for the bovine
PBMC) while a low level of proliferating cells was detected
in untreated cells (1.5 to 3% for the mouse cells and 10%
to 11% for the bovine PBMC). Compared to these data,
ELP stimulation did not elicit cell proliferation from mouse
spleen cells (2% to 2.5%) nor from bovine cells (10% to
13%).
The eﬀect of purified ELP was also assessed on mouse
or bovine dendritic cells (DC), because DC are key play-
ers in the immune response. Compared to the negative
(untreated cells) and positive (LPS for mBM-DC and
LPS/IFNγ/zymosan for Bo-Mo-DC) controls, ELP did not
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Figure 5: Assessment of the cytotoxicity of tobacco leaf extracts
(TLEs) from nongenetically modified tobacco plants on mouse and
bovine cells. TLE was added to mouse spleen cells and to bovine
PBMC (2 × 106 cells/mL) with final dilutions ranging from 0.01%
to 6% (v/v). The concentration of total soluble proteins (TSPs)
in the TLE dilutions was determined by the Bradford assay. The
percentage of dead cells was measured 4 days later by flow cytometry
after propidium iodide labeling (2 μL). The histogram presents the
mean percentage (± SD) of dead cells (X-axis) induced by each TSP
concentration (Y-axis) for each animal cell type.
trigger expression of the maturation markers (MHCII,
CD40, CD80, and CD86) on mouse or bovine DC.
Figure 4(b) presents the results (mean± SD) obtained for the
mBM-DC in two duplicate experiments. LPS stimulation,
compared to untreated cells, elicited an increase of at least
20% of the expression of the major histocompatibility
complex class II molecules (MHC II, 22%), CD40 (20%)
and CD80 (22%) and of 11% for the CD86 expression.
Instead, no significant change in the expression of these
markers was detected in the presence of 2.5 or 5 μg/mL
of ELP. For the Bo-Mo-DC, more variability was observed
between the two experiments due to variable basal levels
of expression of MHCII, CD40, CD80, and CD86 on
untreated cells. This likely results from more heterogeneous
DC populations compared to mBM-DC. Nevertheless, in
each experiment, ELP stimulation of Bo-Mo-DC, compared
to the controls, did not trigger any significant expression of
the cell maturation markers.
Since no ELP immunomodulatory eﬀect was detected,
the ELP motif should have no impact on TBAg immuno-
genicity. Consequently, there was no need to remove the
100xELP chain from the plant-expressed TBAg-ELP product.
3.3. Evaluation of the Toxicity of Tobacco Leaf Extracts. To
evaluate the potential cytotoxicity of crude tobacco leaf
extracts (TLEs), in vitro assays and in vivo experiments
in piglets were carried out using nongenetically modified
tobacco plants.
3.3.1. In Vitro Experiments on Mouse and Bovine Cells. The
mouse spleen cells and bovine PBMC were incubated 4
days with TLE dilutions varying from 0.01% to 6%. The
concentration of total soluble proteins (TSPs) in the TLE
ranged from 0.33 μg/mL in the 0.01% dilution to 198 μg/mL
in the 6% dilution. A dose-dependent toxicity on both
animal cells was observed in the presence of TLE as shown
in Figure 5. The results are expressed as the mean percentage
of dead cells (± SD), measured for each TLE dilution, from 2
experiments performed in duplicate. Up to a concentration
of 66 μg/mL of TSP (2% TLE), the mean percentage of
dead cells slightly increased from 18.23% ± 1.98% for the
murine cells and 21.55%±2.11% for the bovine cells without
TLE to 34.61% ± 4.38% and 32.48% ± 2.74%, respectively,
for a 2% dilution. For TLE dilutions corresponding to
higher concentrations of TSP (132 and 198 μg/mL), the mean
percentage of dead cells strongly increased, reaching 68.24%
(±3.35%) for the murine cells and 66.31% (±1.03%) for the
bovine cells for the 6% dilution.
Considering the cytotoxicity induced by the tobacco
leave soluble extract, ITC-purified TBAg-ELP was used for
evaluation of the plant-expressed TBAg immunogenicity in
mice. Indeed, for TBAg-transgenic tobacco plants, the ratio
TBAg/TSP was estimated to be 4%. Therefore, the TSP doses
required to immunize mice with 5 to 10 μg of TBAg would be,
respectively, 125 and 250 μg of TSP from TBAg-transgenic
plants. However, our results suggested that, after 4 days of
contact, these doses of tobacco soluble proteins can induce
cytotoxicity in half to two third of the initial cell population.
3.3.2. In Vivo Experiments on Neonate Piglets. The TLE
clinical impact was assessed by injecting neonate piglets with
TLE containing 3.6 mg of TSP. In this experiment, neonate
piglets were used to increase sensitivity to TLEs toxicity.
In contrast to the in vitro data, the in vivo experiment
showed no significant change in piglet temperature or
clinical status after three intraperitoneal injections (data
not shown). Accordingly, to assess plant-expressed TBAg
immunogenicity in the piglet model, crude TLE from TBAg-
ELP-transgenic tobacco plants was used.
3.4. In Vivo Immunogenicity Evaluation of the Plant-Expressed
TBAg-ELP Fusion Protein
3.4.1. Mouse Experiments. The first experiment set out
to evaluate the clinical impact and immunogenicity of
the plant-expressed ITC-purified TBAg-ELP compared, as
a positive control, to M. tuberculosis CFP. The anti-CFP
humoral response was tested to assess the ability of the
TBAg-ELP-induced antibodies to recognize the native M.
tuberculosis ESAT-6 and Ag85B contained in the CFP.
None of the immunized mice developed any clinical side
eﬀects. The two groups of CFP-immunized mice exhibited a
strong anti-CFP dose-dependant humoral response detected
on day 42 and lasting up to day 84, compared to the control
group (Figure 6, upper graph). The group of mice receiving
10 μg of TBAg-ELP, but not 5 μg, was also characterized
by an anti-CFP antibody response with a peak observed
on day 42 (Figure 6, lower graph). The immunogenicity
of the plant-expressed TBAg was revealed by its ability to
trigger TBAg-specific antibodies able to recognize the native
M. tuberculosis ESAT-6 and Ag85B. The diﬀerence in the
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Figure 6: Kinetic of the anti-CFP humoral response from CFP
and TBAg-immunized mice. Five groups of 4 mice were analysed.
Two positive groups were injected with 5 and 10 μg of CFP (upper
graph) while the negative control group received 0.9% NaCl (both
graphs). Two other groups were immunized with 2 doses (5 and
10 μg) of purified TBAg-ELP (lower graph). Antigens were delivered
in DDA/MPL by 3 SC injections on day 0, 14, and 28. Blood samples
were taken on day 0, 42, and 84 and pooled. The anti-CFP response
was analysed by ELISA using plates coated with 1 μg/well of CFP.
Diluted sera (1/50) were tested in triplicate. Total Igs were detected
with HRP-labeled rabbit antimouse Ig antibodies. Absorbance was
measured at 450 nm after TMB revelation and H2SO4 treatment.
Results are presented as mean ± standard deviation (SD).
intensity level of CFP-induced and TBAg-induced antibodies
was due to the multiple proteins contained within the CFP,
while only ESAT-6 and Ag85B were present in the TBAg-ELP.
The reduced intensity and short duration of the antibody
response showed the need for an antigen delivery system able
to enhance the immune response.
To that end, a cationic liposome-based delivery system
was tested. None of the mice showed any clinical signs. The
anti-CFP humoral response detected for the TBAg-ELP and
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Figure 7: Delayed-type hypersensitivity response in TBAg-ELP
and CFP-immunized mice. Groups of 4 mice were immunized, as
described above, with 10 μg of TBAg-ELP mixed with DDA/MPL
or loaded in liposomes. The positive control group was injected
with 10 μg of CFP/DDA/MPL and the negative control group with
0.9% NaCl. A skin test was performed on each animal on day 56
to evaluate the delayed-type hypersensitivity (DTH) reaction. Mice
received an intradermal injection of 10 μg of M. bovis PPD (in
40 μL of 0.9% NaCl) into the right-hind footpad and, as a control,
0.9% NaCl into the left-hind footpad. The diameter of the specific
swelling was measured 24 h later and data were expressed as the
mean (± SD) of the diﬀerence between right and left footpads
for each group of mice (n = 4). The statistical analysis compared
(1) the CFP group versus the negative control group and (2)
the TBAg/liposome group versus the TBAg/DDA/MPL group and
the negative control group. P-values less than .05 were considered
significant (∗) and less than .01 highly significant (∗∗).
CFP mice groups was similar to the one observed in the first
experiment. No significant change was noticed for the 10 μg
of TBAg-ELP whether in liposomes or in DDA/MPL (data
not shown).
The tuberculin skin test was carried out, as indicative
of the TBAg-induced cellular immune response. Similar
to the CFP ELISA, this test was performed with PPD
containing native mycobacterial proteins. Although the DTH
response was moderate, it revealed the significant increase
(P < .05) in TBAg-ELP-primed lymphocytes on day 56
with liposome delivery compared to DDA/MPL (Figure 7).
The CFP-immunized mice were characterized by a highly
significant DTH response (P < .01). The diameter of the
footpad swelling in the CFP group reached 503 ± 22μm,
while it was 388± 51μm for TBAg-ELP/liposome group and
only 143 ± 58μm for the TBAg-ELP/DDA/MPL or 95 ±
50μm for the negative control groups.
3.4.2. Piglet Experiment. The immunogenicity of the TBAg-
ELP transgenic tobacco leaf crude extract (TLE-TBAg-ELP)
was assessed in comparison to E. coli recombinant ESAT-6
protein. In this experiment, the piglets older (33–61 days old)
than the neonates piglets, used for the toxicity assay, were
selected because of the maturity of their immune system.
ELISA analyses showed that injections with purified
recombinant ESAT-6 alone (group 1) induced an IgG anti-
body response to ESAT-6 while injections of TLE-TBAg-ELP
10 Journal of Biomedicine and Biotechnology
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Figure 8: Assessment of the humoral response during the piglet experiment. Four groups of 2 piglets were immunized on days 0, 7,
and 14 through an intradermal route. Group 1 was injected with E. coli ESAT-6, group 2 with TLE-TBAg-ELP, group 3 with E. coli
ESAT-6 and boosted two times with TLE-TBAg-ELP, and group 4 received PBS, as the control. Sera were harvested weekly and diluted
(10−2, 10−3, and 10−4). The IgG antibody response against the diﬀerent TB antigens was measured by ELISA (a) and Western blot (b). (a)
ELISA analysis of the piglet IgG response on day 28 against E. coli ESAT-6, Ag85B, and plant-expressed TBAg-ELP. Results represent the
mean optical densities (± SEM, n = 2, each in triplicate). (b) Western blot analysis of the piglet antibody response on day 0 and 28. Lane 1:
rabbit antisera, lanes 2 and 6: sera from piglets immunized with E. coli ESAT-6 (group 1), lanes 3 and 7: sera from piglets immunized with
TLE-TBAg-ELP (group 2), lanes 4 and 8: sera from piglets sensitized with E. coli ESAT-6 and boosted with TLE-TBAg-ELP (group 3), and
lanes 5 and 9: sera from control piglets receiving PBS (group 4).
(group 2) induced an IgG antibody response to Ag85B
only (Figure 8(a)). However, sensitization with bacterial
ESAT-6 and boosting with the TLE-TBAg-ELP (group 3)
induced an IgG response to both ESAT-6 and Ag85B (Figure
8(a)).
Western blot analysis (Figure 8(b)) gave much the same
data showing that results were independent of antigen
conformation. Thus, immunization with TLE-TBAg-ELP
was not suﬃcient to induce an antibody response against
both antigens, showing that ESAT-6 sensitization is essential.
In both experiments (ELISA and Western blot), control
piglets immunized with PBS and Freund adjuvant neither
elicited any antibody response against ESAT-6, Ag85B nor
toward TLE-TBAg-ELP. This result showed that the antibody
responses detected in piglets from group 1, 2, and 3 were
antigen specific.
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4. Discussion
This study explored the possibility of genetically engineering
plants to produce mycobacterial antigens for the develop-
ment of a subunit vaccine against tuberculosis (TB). In order
to achieve this, fusion to the elastin-like peptides (ELP) was
the strategy adopted for the plant expression system. The
findings showed that the ELP fusion technology led to an
eﬃcient and stable expression of the mycobacterial Ag85B-
ESAT-6 proteins, as an ELP fusion in tobacco plants, while
maintaining normal growth and morphology. The level of
production for this TBAg-ELP fusion protein reached 4%
of the tobacco leaf total soluble proteins (TSP) for the
best producer plants. The plant-expressed TBAg-ELP fusion
protein was targeted to the lumen of the ER because higher
accumulation of secreted recombinant proteins is reported
in that intracellular compartment [28]. The ELP expression
system had proved its eﬃcacy since commonly lower levels
of foreign proteins accumulate in plants [14, 59]. However,
with certain expression systems and conditions, expression
levels of plant-made foreign protein have been reported to
achieve 20% and more TSP [14, 17]. Nevertheless, a previous
study expressing ESAT-6 in Nicotiana tabacum using a
viral vector mentioned levels ranging from 0.5% to 1% of
TSP [60].
The immunogenicity and the safety of the plant-
expressed TBAg were compared and confirmed in both
mouse and piglet models. Mice were used as a reference
laboratory model and compared to piglets that were used
as a preclinical model of human vaccination, based on
similarities between swine and human immune responses.
Bovine TB was also an objective; however, no small animal
model can replace bovine. With cost constraints being a
limiting factor for in vivo cattle studies, only in vitro
experiments with bovine immune cells were carried out.
Mice and piglets injected with purified TBAg-ELP or with
crude tobacco leaf extracts (TLE), respectively, exhibited a
mycobacterial-specific immune response with no side eﬀects.
In mice, the immunogenicity of plant-purified TBAg-
ELP was evaluated and compared to two immunogenic
preparations of native M. tuberculosis proteins, namely,
CFP (culture filtrate proteins) and PPD (purified protein
derivatives). Our findings demonstrated that both the TBAg-
induced antibodies and primed T-cells were able to recognize
the native proteins contained in the mycobacterial CFP or
PPD. Ag85 is a prominent component of these preparations
and ESAT-6 is also present in significant proportion [61].
Hence, the antibody and T-cell reactivity might be pre-
dominantly directed against Ag85B but possibly also against
ESAT-6.
In piglets, the immunogenicity of crude extracts of
TBAg-ELP transgenic tobacco leaves (TLE-TBAg-ELP) was
assessed. The piglet humoral response was analysed by
Western blot and by using three ELISAs, based on E. coli
ESAT-6, E. coli Ag85B, and TLE containing TBAg-ELP,
respectively. The results revealed the main reactivity of the
TLE-TBAg-ELP-induced antibodies against Ag85B. Indeed,
the piglet antibodies only recognized the plant-produced
TBAg-ELP and E. coli Ag85B.
The findings in the two animal models confirm the
maintenance of bacterial Ag85B B-cell epitopes in the TBAg
fusion protein produced by the tobacco plants.
In contrast, the absence of E. coli ESAT-6 recognition
by the TLE-TBAg-ELP-immunized piglet sera (group 2)
and of the ESAT-6 within the plant-expressed TBAg by the
E. coli ESAT-6-injected piglet sera (group 1) suggested a
diﬀerence in B-cell epitopes between bacterial and plant-
expressed ESAT-6. This diﬀerence should not result from
the TBAg gene cassette since it was designed to respect
the protein sequence. Moreover, in Western blot analysis
under denatured conditions, the plant-expressed TBAg-ELP
reacted with rabbit anti-E. coli ESAT-6 antisera (data not
shown). Consequently, linear ESAT-6 B-epitope sequences
were conserved after plant expression. Nevertheless, within
the transgenic tobacco leaf extract (TLE-TBAg-ELP), ESAT-6
was located between Ag85B and ELP. Expression and folding
of one of these two proteins might hide part of ESAT-6, thus
hindering antibody production in piglets.
Cell-mediated responses are known to play a key role
in human and bovine TB [7, 62, 63]. To address this
point, the mouse model and the delayed hypersensitivity test
(DTH), which correlates with the frequency of mycobacteria-
primed T-cells, were used [64–66]. Our findings showed
that the plant-produced TBAg-ELP was able to trigger a T-
cell response in mice, probably of the CD4 T-cell subtype.
The higher frequency of TBAg-primed T-cells observed
with the liposome delivery system probably resulted from
more eﬃcient TBAg interaction with the host antigen-
presenting cells. The DTH response to PPD confirmed the
TBAg-primed T-cell ability to recognize native mycobacterial
proteins. Ag85B is probably the main target but ESAT-6
should be involved too. ESAT-6 is, indeed, also a T-cell
immunogen and contains overlapping B- and T-cell epitopes
[67]. Furthermore, Rigano and colleagues [68] reported the
induction of a CD4 T-cell immune response by feeding mice
with an Arabidopsis-made ESAT-6 fused to the E. coli heat-
labile enterotoxin (LTB).
Our results thus showed the expression of an Ag85B-
ESAT-6 fusion protein in leaves of transgenic tobacco plants
able to trigger host antibodies and T-cells recognizing
mycobacterial Ag85B and probably ESAT-6.
Production of a subunit vaccine against tuberculosis in
plants might be a promising strategy to overcome the cost
constraints linked to large vaccination campaigns, mainly
in developing countries where such vaccines are needed the
most. Indeed, plants can be used as cost-eﬀective biofactories
for foreign protein production but also, for food plants,
as eﬃcient oral antigen delivery system [15, 17]. It has
been estimated that proteins can be produced in plants at
a cost 10–50-fold less than in E. coli [22]. Nevertheless,
several challenges still need to be overcome before plant-
based vaccines become more widely available [16, 17].
Environmental concern and public acceptance are major
ones. However, glasshouse-based plant production, rather
than in open fields, might resolve this problem. To that end,
high levels of foreign protein expression and consistency of
those expression levels will allow cost eﬀective production
in contained facilities. The ELP fusion technology provides
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many advantages for large-scale production of biologicals
[32]. This includes increased yields [21–23] and simple
downstream processing by inverse transition cycling [22, 24,
27, 29]. Our study confirmed that ELP has no immunomod-
ulating activity. This finding is in accordance with the lack
of immunogenicity already described for ELP, its biodegrad-
ability and biocompatibility for human tissues, tissue fluids,
and blood [33, 69]. Fusion of a protein to ELP can also
promote particle aggregation. This thermally responsive ELP
strategy might lead to interesting delivery systems, able to
form a depot eﬀect into a target compartment with sustained
release of the antigens [70].
In conclusion, this study presents the first results of an
eﬃcient plant-expression system, relying on the elastin-like
peptide fusion strategy, to produce a safe and immunogenic
mycobacterial Ag85B-ESAT-6 fusion protein as a potential
vaccine candidate against TB.
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